Table 4.
Information sources on the HPV-vaccine used by public health nurses (PHN) and GPs in Northern Norway in proportions (%) and 95% CI.a
| GPs (n = 121) % | Public health nurses (n = 99) % | pb | |
|---|---|---|---|
| NIPH Booklet (ref. [26]) | 30 (22–38) | 98 (95–100) | 0.000 |
| NIPH Rapport (ref. [10)) | 30 (22–38) | 85 (79–91) | 0.000 |
| NIPH webside | 33 (25–41) | 90 (84–96) | 0.000 |
| Nationwide courses before initiation of vaccination programme | 3 (0–6) | 63 (53–73) | 0.000c |
| Pharmaceutical Industry, information brochuresd | 50 (41–59) | 88 (82–94) | 0.000 |
| Pharma courses | 6 (2–10) | 19 (11–27) | 0.002 |
| Pharma evening meetings | 22 (15–29) | 22 (14–30) | 0.896 |
a
One year after the inclusion of the HPV vaccine in the childhood vaccination programme.
b
Significant differences between GPs and PHN in bold, p value based on Chi square test.
c
Fisher’s Exact Test.
d
Information brochures on HPV vaccine sent by post to all public health nurses and GPs from pharmaceutical industry.